Business
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that an abstract highlighting the results from the Company’s STRIVE-ON Phase 3 Safety Trial has been ac
About this update from Grace Therapeutics, Inc.
[{"type":"image","alt":"Grace Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Grace Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":238,"height":52,"url":"https://media.zenfs.com/en/globenewswire.com/d9c2bb0e1d56296ef30bd84c47a14138"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LdliIJ9szS3SzFAocDThaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTky/https://media.zenfs.com/en/globenewswire.com/d9c2bb0e1d56296ef30bd84c47a14138","width":238,"height":52}},"lazy":false},{"type":"text","content":"PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that an abstract highlighting the results from the Company’s STRIVE-ON Phase 3 Safety Trial has been accepted for presentation at the upcoming 2026 American Academy of Neurology annual meeting, to be held April 18-22, 2026 in Chicago, IL.","length":640,"tagName":"p"},{"type":"text","content":"The STRIVE-ON Trial results will be presented as a poster on April 21, 2026. Details are as follows:","length":100,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:13%;width:13%;min-width:13%;vertical-align:middle;text-align:left;padding-left:20.0px;vertical-align:top;","val":[{"type":"text","content":"Session:","length":8,"tagName":"p","attribs":{}}]},{"style":"max-width:2%;width:2%;min-width:2%;vertical-align:middle;text-align:left;padding-left:20.0px;vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"max-width:85%;width:85%;min-width:85%;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"S21: Neurocritical Care","length":23,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:middle;text-align:left;padding-left:20.0px;vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"vertical-align:middle;text-align:left;padding-left:20.0px;vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attr...